Drugs / HMPL-506
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06387082 | May 2024 → Oct 2027 expected | hematopoietic and lymphoid cell neoplasm | Hutchmed | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-04-05 | Hutchison Medipharma Limited | Results HUTCHMED Highlights Data to be Presented at AACR Congress 2024 hutch-med.com ↗
Compared with five other menin inhibitors in clinical development, HMPL-506 showed the stronger inhibitory potency in MLL-rearranged and NPM1 mutant leukemia cell line models. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-06-07 | Hutchison Medipharma Limited | HUTCHMED Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China hutch-med.com ↗ |
| 2024-04-05 | Hutchison Medipharma Limited | HUTCHMED Highlights Data to be Presented at AACR Congress 2024 hutch-med.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HMPL-506 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06387082 ↗ |
| Route | Oral | “administered orally” NCT06387082 ↗ |